Developed a laparoscopic surgical technique to enable the minimally invasive implantation of ACT-IOP-003 device onto the pancreas. ACT-IOP-003, Focal Medical’s targeted therapeutic product, is designed to safely achieve a high concentration of chemotherapeutic in the target organ, via non-circulatory pathways,…
Successful completion of development of a precision therapeutic system designed to safely achieve high concentration of chemotherapeutic in target organ, via non-circulatory pathways and with little to no systemic drug exposure and associated toxicity. Cary, NC October 25, 2023 —…
This investment is in addition to the previously announced Series A investment of $5.5 million lead by Khosla Venture. Read More
The capital will be used to fund initial clinical development of the company’s ACT-IOP-003 local chemotherapy system for the treatment of locally advanced non-resectable and borderline resectable pancreatic cancer. Read More
Raleigh, NC, June 30th, 2020 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company focused on developing iontophoresis drug delivery devices, today announced that the United States Patent and Trademark Office (USPTO) has issued US Patent 10,695,562 B2. Embodiments…
Raleigh, NC, March 20th, 2020 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company developing the ACT Implantable Iontophoresis Chemotherapy Delivery Device with gemcitabine (ACT-IOP-003), announced today that the Company has submitted an investigational new drug (IND) application to…
Raleigh, NC, August 30th, 2019 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company focused on developing iontophoresis drug delivery devices, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for…
Raleigh, NC, August 22nd, 2019 – Advanced Chemotherapy Technologies, Inc. (www.advancedchemotech.com), a combination drug-device company focused on developing iontophoresis drug delivery devices, today announced receipt of a $771,376 grant from the National Cancer Institute of the National Institutes of Health…
Tony Voiers joined Advanced Chemotherapy Technologies as CEO after meeting with company co-founder Jen Jen Yeh, a professor of surgery at the UNC School of Medicine. Voiers relies on his experience in engineering and management to run the business, which…
November 18, 2018— Bioscience companies from North Carolina dominated the awards competition at the 20th annual SEBIO Investor and Partnering Forum in Atlanta this month, with nine Tar Heel firms earning recognition. Read More
